High Cost of WGS Acting as a Restraint for Market Growth
Though the cost of WGS has been declining on a consistent basis, patients still find the service's price significantly high, especially in the case of cancer, which includes interpretation, analysis and treatment costs. Since the pricing mechanism in the personalized whole genome cancer sequencing is unregulated, private players charge different prices as per the technology used and services offered. Moreover, in the absence of insurance coverage, the out-of-pocket cost to patients fares pretty high.
View full press release